Spring Bank Pharmaceuticals Inc

Spring Bank Pharmaceuticals — F-star Therapeutics — Investor Presentation (November 2020)

31 slides from Spring Bank Pharmaceuticals's investor presentation, Nov 20, 2020

  1. Slide 1: Next Generation Immunotherapies. Overcoming Cancer.

    Q4 2020 Next Generation Immunotherapies. Overcoming Cancer. Exhibit 99.2

  2. Slide 2: Forward-looking statements

    Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These

  3. Slide 3: Our Mission

    We are dedicated to developing next generation immunotherapies to transform the lives of patients with cancer Our Mission

  4. Slide 4: Experienced Management Team

    Experienced Management Team Medical Oncologist with 25+ years' experience in clinical research in Europe and US Experience in registrational studies, registration strategy and drug approval Louis Kayitalire CMO, MD 25+ years leading financial operations in public and private companies Proven track r

  5. Slide 5: Next Generation Bispecifics to Activate the Immune System

    2 natural binding sites 2 new Fc antigen binding (Fcab) sites FcgR null Natural human antibody means easier manufacturing and favorable safety Targeted enhanced bispecific activity through four binding sites (tetravalent) Next Generation Bispecifics to Activate the Immune System Receptor clustering

  6. Slide 6: Highly Versatile Platform Technology

    Highly Versatile Platform Technology Fcabs to 11 targets including: CD137, OX40, LAG-3, EGFR, HER-2, PD-L1 mAb2 Bispecifics* Trispecifics Fc Fusions* Monovalent Bispecifics Rapid “PLUG & PLAY” to multiple formats *Already in clinic

  7. Slide 7: Bispecific Differentiation Through Crosslinking, Clustering and Conditionality

    Bispecific Differentiation Through Crosslinking, Clustering and Conditionality Traditional Antibody Antibody Combination Heterodimeric Bispecific Antibody Alternative Scaffold Bispecific Fragment Bispecific incl BITEs F-star mAb2 Bispecific crosslinking Conditional activity Tetravalent clustering Ig

  8. Slide 8: Next Generation Immunotherapies for Well Defined Tumor Settings

    Next Generation Immunotherapies for Well Defined Tumor Settings 2020 2021 Clinical Programs Targets Opportunity Current Status Clinical Stage Preclinical Ph1 Ph2 FS118 LAG-3/PD-L1 Rescuing CPI treatment failures Q1 2021 US Phase 2 start in PD-1 resistant head & neck cancer patients FS120 OX40/CD137

  9. Slide 9: Long Term Positioning of F-star's Programs in First and Second Line

    1st line Chemotherapy IO Combination (e.g. with IO, TKI, CTx) IO monotherapy 2nd line IO Combination (e.g. with IO, TKI, CTx) Non –IO (Primary resistance) IO monotherapy Typically PD-L1 low Typically PD-L1 high Long Term Positioning of F-star’s Programs in First and Second Line FS222 FS118 FS120 IO

  10. Slide 10: FS118 Rescuing CPI-treatment failures

    First-in-class LAG-3/PD-L1 bispecific antibody Well tolerated with long term dosing Encouraging signs of clinical activity Novel mechanism of action for acquired resistance patients Q1 2021 US POC start in PD-1 resistant head & neck cancer patients FS118 Rescuing CPI-treatment failures LAG-3 PD-L1

  11. Slide 11: Phase I in Heavily-Pretreated PD-(L)1 Refractory Patients

    Phase I in Heavily-Pretreated Cancer Patients that are PD-(L)1 Refractory (n=43) Soluble LAG-3 Well tolerated up to 20 mg/kg Clinical benefit observed in tumors co-expressing LAG-3 /PD-L1 59% DCR in acquired resistant patients Recommended Phase 2 dose 10 mg/kg Prolonged increase in levels of soluble

  12. Slide 12: Proof of Concept in PD-1 Acquired Resistance in Head & Neck Cancer

    Proof of Concept in PD-1 Acquired Resistance in Head & Neck Cancer Stage 1 10 Evaluable patients (LAG-3+/PD-L1+) FS118 monotherapy futility analysis Objective: Demonstrate efficacy in a focused H&N study with PD-L1 and LAG-3 positive tumors Stage 2 12 Evaluable patients (LAG-3+/PD-L1+) FS118 monothe

  13. Slide 13: FS118 Development Plan in LAG-3+/PD-L1+ Patients

    FS118 Development Plan in LAG-3+/PD-L1+ Patients 2021 2022 2023 2024 2025 2026 Clinical Endpoint Ph I/II Monotherapy Ph II Combo Response rate Basket protocol (PD-L1+/LAG-3+) Response rate Ph III H&N: FS118 combo vs SoC Progression free survival Overall survival NSCLC| Mesothelioma| HCC | SCLC etc 2

  14. Slide 14: FS118 Clinical Positioning: Rescuing Checkpoint Inhibitor Failures

    FS118 Clinical Positioning: Rescuing Checkpoint Inhibitor Failures FS118: Rescuing CPI-treatment failures FS118 2L: Head & Neck | NSCLC | Mesothelioma| HCC | SCLC | 1st line Chemotherapy IO Combination (e.g. with IO, TKI, CTx) IO monotherapy 2nd line IO Combination (e.g. with IO, TKI, CTx) Non –IO (

  15. Slide 15: FS120 Improving CPI and chemotherapy outcomes

    FS120 Improving CPI and chemotherapy outcomes First-in-class CD137/OX40 mAb² dual agonist bispecific antibody Dual activation of CD8+ and CD4+ T cells. Destabilisation of Tregs Conditionally active and FcgR null for improved safety Q4 2020 US Phase 1 start: monotherapy and PD-1 combo OX40 CD137

  16. Slide 16: Biomarker Driven Tumor Selection

    Biomarker Driven Tumor Selection Correlation coefficient (co-expression) Genome Atlas (TCGA) data OX40 & CD137 in select tumors Target(s) gene expression (normalised to median) CD137 OX40 Lung Biopsy #1 Lung Biopsy #2 Co-expression by IHC Lung Cancer Bladder Cancer Head & Neck Cancer Target tumor ty

  17. Slide 17: FS120 First in Human Study Design

    FS120 First in Human Study Design Part 1a Monotherapy Dose Escalation FS120 Monotherapy Part 1b PD-1 Combination FS120 plus PD-1 mAb Part 1c Combination Cohorts COHORT A NSCLC Objective: Early demonstration of combination improving CPI efficacy COHORT B Head & Neck COHORT C SCLC COHORT D Bladder Pri

  18. Slide 18: FS120 Development Plan: Combination with PD-1 in Early Lines of Therapy

    FS120 Development Plan: Combination with PD-1 in Early Lines of Therapy 2020 2021 2022 2023 2024 Clinical Endpoint Phase I: Part A Monotherapy Part B PD-1 Combination Part C PD-1 Combination tumor specific expansion Safety, PK, biomarker, RP2D for mono and combo Response rate, Duration of response P

  19. Slide 19: FS120 Clinical Positioning: Improving CPI and Chemotherapy Outcomes

    FS120 Clinical Positioning: Improving CPI and Chemotherapy Outcomes FS120 1L: Head & Neck | NSCLC | Bladder| SCLC | 1st line Chemotherapy IO Combination (e.g. with IO, TKI, CTx) IO monotherapy 2nd line IO Combination (e.g. with IO, TKI, CTx) Non –IO (Primary resistance) IO monotherapy Typically PD-L

  20. Slide 20: FS222 Improving outcomes in PD-L1 low tumors

    FS222 Improving outcomes in PD-L1 low tumors CD137/PD-L1 mAb² bispecific antibody Redirecting activated immune cells to the tumor Q1 2021 European Phase 1 start CD137 PD-L1

  21. Slide 21: FS222 First in Human Study Design

    FS222 First in Human Study Design Part 1a Monotherapy Dose Escalation FS222 monotherapy RP2D Primary Objectives: Safety & RP2D Secondary Objectives: Disease response, immunogenicity, PK/PD, biomarkers Part 1b Expansion Cohorts COHORT A NSCLC (targeted subgroup) Objective: Early demonstration of clin

  22. Slide 22: Superior mAb2 Activity Compared to Other Formats

    Superior mAb2 Activity Compared to Other Formats FS222 is potent, well tolerated and has the potential for clinical differentiation in PD-L1 low setting 1mg/kg (approx. 12 mice/group) Activity also observed in CT26 model Comparison to other bispecific formats 100% Tumor-free Survival of MC38 tumor-b

  23. Slide 23: Targeting Tumors with CD137/PD-L1 Co-expression

    Targeting Tumors with CD137/PD-L1 Co-expression Correlation coefficient (co-expression) Genome Atlas (TCGA) data PD-L1 & CD137 in select tumors Target(s) gene expression (normalised to median) Esophageal Cancer Ovarian Cancer Colorectal Cancer Low PD-L1: Unique opportunity Better than competition PD

  24. Slide 24: FS222 Development Plan

    PD-L1 FS222 Development Plan 2021 2022 2023 2024 Clinical Endpoint Phase I: First-in-Human Tumor specific expansion Tumor-specific expansions Safety, PK, biomarkers, RP2D for mono Response rate, Duration of response Phase II/III: Clinical program acceleration Progression free survival Overall surviv

  25. Slide 25: FS222 Clinical Positioning: Improving Outcomes in PD-L1 Low Tumors

    1st line Chemotherapy IO Combination (e.g. with IO, TKI, CTx) IO monotherapy 2nd line IO Combination (e.g. with IO, TKI, CTx) Non –IO (Primary resistance) IO monotherapy Typically PD-L1 low Typically PD-L1 high FS222 Clinical Positioning: Improving Outcomes in PD-L1 Low Tumors FS222 1L: NSCLC (targe

  26. Slide 26: SB 11285: Improving CPI outcomes

    SB 11285: Improving CPI outcomes Second generation STING agonist for intravenous administration Preclinical studies indicate potential advantages over intra-tumoral STING agonists Phase 1/2 trial, including combination with TecentriqTM, ongoing No drug-related Serious Adverse Events have been report

  27. Slide 27: SB 11285 Phase 1a/1b Trial Design (ongoing)

    SB 11285 Phase 1a/1b Trial Design (ongoing) 1° Objectives: Safety & RP2D 2° Objectives: Disease Response, PK/PD, biomarkers Part 1a Monotherapy Dose Escalation SB 11285 Monotherapy Part 1b PD-L1 Combination Dose Escalation SB 11285 plus atezolizumab RP2D Part 1c Combination Expansion Cohorts COHORT

  28. Slide 28: SB 11285 Clinical Positioning: Improving CPI Outcomes

    SB 11285 Clinical Positioning: Improving CPI Outcomes 1st line Chemotherapy IO Combination (e.g. with IO, TKI, CTx) IO monotherapy 2nd line IO Combination (e.g. with IO, TKI, CTx) Non –IO (Primary resistance) IO monotherapy Typically PD-L1 low Typically PD-L1 high SB 11285 1L: Melanoma| Head & Neck

  29. Slide 29: Anticipated Future Data Milestones

    Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Anticipated Future Data Milestones Ongoing additional external clinical validation from third parties FS118 update on phase 2 PoC trial in PD-1 acquired resistance patients FS118 Completion of PoC trial F

  30. Slide 30: Thank you.

    THERAPEUTICS Thank you.

  31. Slide 31: References

    Platform: Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments. DOI: 10.1093/protein/gzx042 Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics. DOI:10.1016/j.ymeth.2018.09.003. Bispecific antibodies: a m

F-star Therapeutics — Investor Presentation (November 2020) on 6ix